Nafadotride

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 584886

CAS#: 390412-29-0

Description: Nafadotride preferential dopamine D3 receptor antagonist.


Price and Availability

Size
Price

Size
Price

Size
Price

Nafadotride is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 584886
Name: Nafadotride
CAS#: 390412-29-0
Chemical Formula: C22H27N3O2
Exact Mass: 365.2103
Molecular Weight: 365.477
Elemental Analysis: C, 72.30; H, 7.45; N, 11.50; O, 8.76


Synonym: Nafadotride

IUPAC/Chemical Name: N-(((2S)-1-Butylpyrrolidin-2-yl)methyl)-4-cyano-1-methoxy-2-naphthamide

InChi Key: IDZASIQMRGPBCQ-KRWDZBQOSA-N

InChi Code: InChI=1S/C22H27N3O2/c1-3-4-11-25-12-7-8-17(25)15-24-22(26)20-13-16(14-23)18-9-5-6-10-19(18)21(20)27-2/h5-6,9-10,13,17H,3-4,7-8,11-12,15H2,1-2H3,(H,24,26)/t17-/m0/s1

SMILES Code: O=C(NC[C@H]1N(CCCC)CCC1)C2=CC(C#N)=C3C=CC=CC3=C2OC


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>3 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
2934990300


References

1: Banasikowski TJ, MacLeod LS, Beninger RJ. Comparison of nafadotride, CNQX, and haloperidol on acquisition versus expression of amphetamine-conditioned place preference in rats. Behav Pharmacol. 2012 Feb;23(1):89-97. doi: 10.1097/FBP.0b013e32834ecb32. PubMed PMID: 22157177.

2: Sautel F, Griffon N, Sokoloff P, Schwartz JC, Launay C, Simon P, Costentin J, Schoenfelder A, Garrido F, Mann A, et al. Nafadotride, a potent preferential dopamine D3 receptor antagonist, activates locomotion in rodents. J Pharmacol Exp Ther. 1995 Dec;275(3):1239-46. PubMed PMID: 8531087.

3: Kuballa G, Nowak P, Labus Ł, Bortel A, Dabrowska J, Swoboda M, Kwieciński A, Kostrzewa RM, Brus R. Central effects of nafadotride, a dopamine D3 receptor antagonist, in rats. Comparison with haloperidol and clozapine. Pharmacol Rep. 2005 Mar-Apr;57(2):161-9. PubMed PMID: 15886414.

4: Gyertyán I, Sághy K. Effects of dopamine D3 receptor antagonists on spontaneous and agonist-reduced motor activity in NMRI mice and Wistar rats: comparative study with nafadotride, U 99194A and SB 277011. Behav Pharmacol. 2004 Jul;15(4):253-62. PubMed PMID: 15252275.

5: Dall'Olio R, Gaggi R, Voltattorni M, Tanda O, Gandolfi O. Nafadotride administration increases D1 and D1/D2 dopamine receptor mediated behaviors. Behav Pharmacol. 2002 Dec;13(8):633-8. PubMed PMID: 12478213.

6: Banasikowski TJ, Beninger RJ. Reduced expression of haloperidol conditioned catalepsy in rats by the dopamine D3 receptor antagonists nafadotride and NGB 2904. Eur Neuropsychopharmacol. 2012 Oct;22(10):761-8. doi: 10.1016/j.euroneuro.2012.02.004. Epub 2012 Mar 10. PubMed PMID: 22410316.

7: Richtand NM, Logue AD, Welge JA, Perdiue J, Tubbs LJ, Spitzer RH, Sethuraman G, Geracioti TD. The dopamine D3 receptor antagonist nafadotride inhibits development of locomotor sensitization to amphetamine. Brain Res. 2000 Jun 9;867(1-2):239-42. PubMed PMID: 10837819.

8: Audinot V, Newman-Tancredi A, Gobert A, Rivet JM, Brocco M, Lejeune F, Gluck L, Desposte I, Bervoets K, Dekeyne A, Millan MJ. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther. 1998 Oct;287(1):187-97. PubMed PMID: 9765337.

9: Phillips GD, Harmer CJ, Hitchcott PK. Blockade of sensitisation-induced facilitation of appetitive conditioning by post-session intra-amygdala nafadotride. Behav Brain Res. 2002 Aug 21;134(1-2):249-57. PubMed PMID: 12191811.

10: Phillips GD, Harmer CJ, Hitchcott PK. Isolation rearing-induced facilitation of Pavlovian learning: abolition by postsession intra-amygdala nafadotride. Physiol Behav. 2002 Aug;76(4-5):677-84. PubMed PMID: 12127008.

11: Levant B, Garimelli B, Shafer RA, Merchant KM. Increased levels of proneurotensin/neuromedin N mRNA in rat striatum and nucleus accumbens induced by 7-OH-DPAT and nafadotride. Neuropsychopharmacology. 1999 Aug;21(2):304-11. PubMed PMID: 10432478.

12: Levant B, Vansell NR. In vivo occupancy of D2 dopamine receptors by nafadotride. Neuropsychopharmacology. 1997 Aug;17(2):67-71. PubMed PMID: 9252981.

13: Levant B, Cross RS, Pazdernik TL. Alterations in local cerebral glucose utilization produced by D3 dopamine receptor-selective doses of 7-OH-DPAT and nafadotride. Brain Res. 1998 Nov 23;812(1-2):193-9. PubMed PMID: 9813322.

14: Rogóz Z, Kłodzińska A, Maj J. Anxiolytic-like effect of nafadotride and PNU 99194A, dopamine D3 receptor antagonists in animal models. Pol J Pharmacol. 2000 Nov-Dec;52(6):459-62. PubMed PMID: 11334239.

15: Liu XS, Hou Y, Yan TL, Guo YY, Han W, Guan FL, Chen T, Li T. Dopamine D3 receptor-regulated NR2B subunits of N-methyl-d-aspartate receptors in the nucleus accumbens involves in morphine-induced locomotor activity. CNS Neurosci Ther. 2014 Sep;20(9):823-9. doi: 10.1111/cns.12276. Epub 2014 May 2. PubMed PMID: 24797707.

16: Braszko JJ, Wielgat P, Walesiuk A. Effect of D(3) dopamine receptors blockade on the cognitive effects of angiotensin IV in rats. Neuropeptides. 2008 Jun;42(3):301-9. doi: 10.1016/j.npep.2008.02.001. Epub 2008 Mar 24. PubMed PMID: 18359517.

17: Rogóz Z, Skuza G. Repeated imipramine treatment enhances the 7-OH-DPAT-induced hyperactivity in rats: the role of dopamine D2 and D3 receptors. Pol J Pharmacol. 2001 Nov-Dec;53(6):571-6. PubMed PMID: 11985330.

18: Boulougouris V, Castañé A, Robbins TW. Dopamine D2/D3 receptor agonist quinpirole impairs spatial reversal learning in rats: investigation of D3 receptor involvement in persistent behavior. Psychopharmacology (Berl). 2009 Mar;202(4):611-20. doi: 10.1007/s00213-008-1341-2. Epub 2008 Oct 3. PubMed PMID: 18836703.

19: Moreno M, Economidou D, Mar AC, López-Granero C, Caprioli D, Theobald DE, Fernando A, Newman AH, Robbins TW, Dalley JW. Divergent effects of D₂/₃ receptor activation in the nucleus accumbens core and shell on impulsivity and locomotor activity in high and low impulsive rats. Psychopharmacology (Berl). 2013 Jul;228(1):19-30. doi: 10.1007/s00213-013-3010-3. Epub 2013 Feb 14. PubMed PMID: 23407782; PubMed Central PMCID: PMC3676742.

20: Besson M, Belin D, McNamara R, Theobald DE, Castel A, Beckett VL, Crittenden BM, Newman AH, Everitt BJ, Robbins TW, Dalley JW. Dissociable control of impulsivity in rats by dopamine d2/3 receptors in the core and shell subregions of the nucleus accumbens. Neuropsychopharmacology. 2010 Jan;35(2):560-9. doi: 10.1038/npp.2009.162. PubMed PMID: 19847161; PubMed Central PMCID: PMC3055378.